Microstructure-Thermal Property Relationships of Poly (Ethylene Glycol-

copolymer crystallinity micelle microstructure thermal behaviour

Journal

Polymers
ISSN: 2073-4360
Titre abrégé: Polymers (Basel)
Pays: Switzerland
ID NLM: 101545357

Informations de publication

Date de publication:
16 Oct 2022
Historique:
received: 30 09 2022
revised: 12 10 2022
accepted: 13 10 2022
entrez: 27 10 2022
pubmed: 28 10 2022
medline: 28 10 2022
Statut: epublish

Résumé

The crystallinity of polymers strongly affects their properties. For block copolymers, whereby two crystallisable blocks are covalently tethered to one another, the molecular weight of the individual blocks and their relative weight fraction are important structural parameters that control their crystallisation. In the case of block copolymer micelles, these parameters can influence the crystallinity of the core, which has implications for drug encapsulation and release. Therefore, in this study, we aimed to determine how the microstructure of poly(ethylene glycol-b-caprolactone) (PEG-b-PCL) copolymers contributes to the crystallinity of their hydrophobic PCL micelle cores. Using a library of PEG-b-PCL copolymers with PEG number-average molecular weight (Mn) values of 2, 5, and 10 kDa and weight fractions of PCL (fPCL) ranging from 0.11 to 0.67, the thermal behaviour and morphology were studied in blends, bulk, and micelles using differential scanning calorimetry (DSC), wide-angle X-ray diffraction (WXRD), and Synchrotron wide-angle X-ray scattering (WAXS). Compared to PEG and PCL homopolymers, the block copolymers displayed reduced crystallinity in the bulk phase and the individual blocks had a large influence on the crystallisation of one another. The fPCL was determined to be the dominant contributor to the extent and order of crystallisation of the two blocks. When fPCL < 0.35, the initial crystallisation of PEG led to an amorphous PCL phase. At fPCL values between 0.35 and 0.65, PEG crystallisation was followed by PCL crystallisation, whereas this behaviour was reversed when fPCL > 0.65. For lyophilised PEG-b-PCL micelles, the crystallinity of the core increased with increasing fPCL, although the core was predominately amorphous for micelles with fPCL < 0.35. These findings contribute to understanding the relationships between copolymer microstructure and micelle core crystallinity that are important for the design and performance of micellar drug delivery systems, and the broader application of polymer micelles.

Identifiants

pubmed: 36297943
pii: polym14204365
doi: 10.3390/polym14204365
pmc: PMC9607102
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Australian Nuclear Science and Technology Organisation
ID : M15933

Références

Polym Chem. 2016 Apr 28;7(16):2836-2846
pubmed: 27358655
Chem Rev. 2018 Jul 25;118(14):6844-6892
pubmed: 29957926
J Control Release. 2005 Dec 5;109(1-3):169-88
pubmed: 16289422
J Control Release. 1998 Jan 23;51(1):1-11
pubmed: 9685899
Int J Pharm. 2016 Mar 16;500(1-2):179-86
pubmed: 26794874
Pharmazie. 2008 Mar;63(3):235-40
pubmed: 18444514
Chem Soc Rev. 2014 Apr 7;43(7):2055-65
pubmed: 24150527
Biomacromolecules. 2004 Sep-Oct;5(5):2042-7
pubmed: 15360322
Iran J Basic Med Sci. 2018 Feb;21(2):153-164
pubmed: 29456812
Mol Pharm. 2011 Jun 6;8(3):932-9
pubmed: 21452866
Prog Biomater. 2015;4(2-4):89-100
pubmed: 26566467
Proc Natl Acad Sci U S A. 1974 May;71(5):1811-5
pubmed: 4525294
Nano Res. 2018 Oct;11(10):4985-4998
pubmed: 30370014
Chem Rev. 2016 Feb 24;116(4):2602-63
pubmed: 26854975
J Colloid Interface Sci. 2022 Jan 15;606(Pt 2):1140-1152
pubmed: 34492457
Int J Pharm. 2015 Aug 15;492(1-2):152-60
pubmed: 26196277
Eur J Pharm Biopharm. 2007 Mar;65(3):259-69
pubmed: 17196803
Biomacromolecules. 2013 Nov 11;14(11):4150-6
pubmed: 24066701
Pharmazie. 2010 May;65(5):343-7
pubmed: 20503926
J Control Release. 2000 Feb 3;63(3):275-86
pubmed: 10601723
Langmuir. 2012 Jul 24;28(29):10653-60
pubmed: 22726124
J Control Release. 2005 May 18;104(2):301-11
pubmed: 15907581

Auteurs

Khandokar Sadique Faisal (KS)

Applied Chemistry and Translational Biomaterials (ACTB) Group, Centre for Pharmaceutical Innovation (CPI), UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.

Andrew J Clulow (AJ)

BioSAXS Beamline, Australian Synchrotron, Australian Nuclear Science and Technology Organisation (ANSTO), Clayton, VIC 3168, Australia.
Drug Delivery, Disposition & Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC 3052, Australia.

Stephanie V MacWilliams (SV)

Surface Interactions and Soft Matter (SISM) Group, Future Industries Institute, UniSA STEM, University of South Australia, Mawson Lakes, SA 5095, Australia.

Todd A Gillam (TA)

Applied Chemistry and Translational Biomaterials (ACTB) Group, Centre for Pharmaceutical Innovation (CPI), UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Surface Interactions and Soft Matter (SISM) Group, Future Industries Institute, UniSA STEM, University of South Australia, Mawson Lakes, SA 5095, Australia.

Ashlyn Austin (A)

Applied Chemistry and Translational Biomaterials (ACTB) Group, Centre for Pharmaceutical Innovation (CPI), UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.

Marta Krasowska (M)

Surface Interactions and Soft Matter (SISM) Group, Future Industries Institute, UniSA STEM, University of South Australia, Mawson Lakes, SA 5095, Australia.

Anton Blencowe (A)

Applied Chemistry and Translational Biomaterials (ACTB) Group, Centre for Pharmaceutical Innovation (CPI), UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.

Classifications MeSH